search
Back to results

Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies

Primary Purpose

Advanced Solid Malignancies

Status
Recruiting
Phase
Phase 1
Locations
International
Study Type
Interventional
Intervention
CFI-402411
Pembrolizumab
Sponsored by
Treadwell Therapeutics, Inc
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Advanced Solid Malignancies focused on measuring advanced tumors, pembro, keytruda, pembrolizumab, 2411, CFI-402411, first in human, first-in-human, hematopoietic progenitor kinase-1 inhibitor, HPK1, advanced solid malignancies, solid malignancies, TWT-101, TWT101, UHN, University Health Network, Treadwell Therapeutics

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Key Inclusion Criteria: Study-Wide Eligibility (Across All Study Parts):

  1. Age > 18 years old
  2. Have progressed after ≥ 1, but no more than 3 regimens of systemic therapies for recurrent / metastatic disease.
  3. Subjects must have measurable disease.
  4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

Part A1: Monotherapy Dose Escalation Inclusion Criteria

1. Histological or cytological confirmation of advanced solid malignancy that is refractory to or not a candidate for current standard treatment(s) and for whom no standard therapy is available.

Part A2: Biomarker-Focused Monotherapy Backfills Inclusion Criteria

  1. Histological or cytological confirmation of one of the advanced cancers listed below;

    • NSCLC
    • SCLC
    • cutaneous melanoma
    • Merkel cell carcinoma
    • squamous cell carcinoma of head and neck, anal canal, or skin
    • urothelial cancer
    • clear cell or non-clear cell renal cell carcinoma
    • triple negative breast cancer
    • endometrial cancer (regardless of MSI status)
    • cervical cancer
    • gastroesophageal cancer
    • hepatocellular cancer
    • any histology if known to be microsatellite-instability high (MSI-H)
  2. Tumors must be refractory to or not a candidate for current standard treatment(s) and for whom no standard therapy exists.

Part A3: Monotherapy Expansion Inclusion Criteria

  1. Histological or cytological confirmation of one of the advanced cancers listed below;

    • NSCLC cancer any histology
    • SCLC
    • cutaneous melanoma
    • Merkel cell carcinoma
    • squamous cell carcinoma of head and neck, anal canal, or skin
    • urothelial cancer
    • clear cell or non-clear cell renal cell carcinoma
    • triple negative breast cancer
    • endometrial cancer (regardless of MSI status)
    • cervical cancer
    • gastroesophageal cancer
    • hepatocellular
    • any histology if known to be microsatellite-instability high (MSI-H)
  2. Tumors must be refractory to or subjects intolerant of current standard treatment(s) and for whom no standard therapies are available.
  3. Optional biopsies: Subjects that consent to optional fresh tumor biopsies must have at least one non-target soft tissue tumor lesion that can be biopsied.

Part B1: CFI-402411 in Combination with Pembrolizumab Dose Escalation Inclusion Criteria

  1. Subjects must be deemed eligible by the Investigator to receive pembrolizumab.
  2. Histological or cytological confirmation of one of the advanced cancers listed below (list may vary in each country, USA shown here);

    • NSCLC cancer any histology
    • SCLC
    • cutaneous melanoma
    • Merkel cell carcinoma
    • squamous cell carcinoma of head and neck, anal canal, or skin
    • urothelial cancer
    • clear cell or non-clear cell renal cell carcinoma
    • triple negative breast cancer
    • endometrial cancer (regardless of MSI status)
    • cervical cancer
    • gastroesophageal cancer
    • hepatocellular cancer
    • any histology if known to be microsatellite-instability high (MSI-H)

Tumors must be refractory to or subjects intolerant of current standard treatment(s) or for whom no standard therapy is available.

Part B2: CFI-402411 in Combination with Pembrolizumab Expansion Inclusion Criteria

  1. Subjects must be deemed eligible by the Investigator to receive pembrolizumab
  2. Histological or cytological confirmation of one of the advanced cancers listed below (list may vary in each country, USA shown here);

    • non-small cell lung cancer any histology
    • SCLC
    • cutaneous melanoma
    • Merkel Cell carcinoma
    • squamous cell carcinoma of head and neck, anal canal, or skin
    • urothelial cancer
    • clear cell or non-clear cell renal cell carcinoma
    • triple negative breast cancer
    • endometrial cancer (regardless of MSI status)
    • gastroesophageal cancer
    • hepatocellular cancer
    • any histology if known to be microsatellite-instability high (MSI-H)
  3. Tumors must be refractory to or subjects intolerant of current standard non-IO treatment(s) or for whom no standard therapy is available.

Key Exclusion Criteria: Study-Wide Eligibility (Across All Study Parts)

Subjects will be excluded from the study if any of the following criteria is met;

  1. Previous treatment with an HPK1 inhibitor in other clinical trials.
  2. Diagnosis of autoimmune-based disease or clinically significant auto-immune disorders.
  3. Have symptomatic congestive heart failure, active angina pectoris or recent myocardial infarction (within 6 mos).
  4. Have chronic atrial fibrillation.
  5. Known central nervous system metastasis.
  6. Stroke or transient ischemic attack, or other ischemic events or thromboembolic events within 3 months of study enrollment.
  7. A history of QTc prolongation or a marked baseline prolongation of QT/QTc interval or a history of additional risk factors for TdP (e.g., heart failure, hypokalemia, family history of Long QT Syndrome).

Sites / Locations

  • University of California San DiegoRecruiting
  • The Angeles ClinicRecruiting
  • Yale Cancer Center
  • Florida Cancer SpecialistsRecruiting
  • START - Mid-WestRecruiting
  • SCRI - NashvilleRecruiting
  • MD AndersonRecruiting
  • START - San AntonioRecruiting
  • Virginia Cancer SpecialistRecruiting
  • Cross Cancer InstituteRecruiting
  • The Ottawa HospitalRecruiting
  • Princess Margaret Cancer CentreRecruiting
  • Prince of Wales HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Arm Label

A1: Monotherapy Escalation

A2: Monotherapy Biomarker

A3: Monotherapy Expansion

B1: Combination Escalation

B2: Combination Expansion

Arm Description

Dose escalation arm with CFI-402411. CFI-402411 is administered orally once daily.

Dose escalation biomarker arm with CFI-402411. CFI-402411 is administered orally once daily.

Dose expansion arm with CFI-402411 at its recommended phase 2 dose.

Dose escalation arm with CFI-402411 in combination with pembrolizumab (at its labeled dose and schedule).

Dose expansion arm with the recommended phase 2 dose of CFI-402411 in combination with pembrolizumab (at its labeled dose and schedule).

Outcomes

Primary Outcome Measures

To assess the incidence of adverse events of CFI-402411 as a single agent and at the recommended phase 2 dose (RP2D).
The number of subjects who experience an adverse event that was possibly related to study drug.
To assess the incidence of adverse events with CFI-402411 in combination with pembrolizumab and at the RP2D.
The number of subjects who experience an adverse event that was possibly related to study drug.
To examine best overall response rate in subjects treated at multiple dose levels of CFI-402411.
Best overall response rate will be summarized by dose cohort and overall using the percent of patients in each tumor response category.
To examine progression free survival in subjects treated at multiple dose levels of CFI-402411.
Time from first dose to disease progression or death whichever occurs first will be calculated and summarized for all patients by dose cohort and overall.

Secondary Outcome Measures

To identify the maximum tolerated dose of single agent CFI-402411 alone and in combination with pembrolizumab.
Safety tables and pharmacokinetic tables will be assessed.
To further assess the incidence of adverse events of CFI-402411.
The number of subjects who experience an adverse event that was possibly related to study drug.
To assess best overall response of CFI-402411 monotherapy and in combination with pembrolizumab.
Best overall response rate will be summarized by dose cohort and overall using the percent of patients in each tumor response category.
To assess overall response rates of CFI-402411 monotherapy and in combination with pembrolizumab.
For all subjects the overall response rates of complete response and partial response will be calculated and summarized by dose cohort and overall.
To assess overall survival of CFI-402411 monotherapy and in combination with pembrolizumab.
The time from first dose until the date of death from any cause will be calculated and summarized for all patients by dose cohort and overall.
To assess progression free survival of CFI-402411 monotherapy and in combination with pembrolizumab.
Time from first dose to disease progression or death whichever occurs first will be calculated and summarized for all patients by dose cohort and overall.
To assess duration of response of CFI-402411 monotherapy and in combination with pembrolizumab.
The time from the first objective response to the time of documented disease progression or death due to any cause, whichever occurs first, will be calculated and summarized for all patients by dose cohort and overall.
To assess the pharmacokinetic profile of CFI-402411 alone when it is administered in combination with pembrolizumab through AUC.
Area under the plasma concentration (AUC) versus time curve from time 0 to time of least measurable concentration tabulated by dose group.
To assess the pharmacokinetic profile of CFI-402411 alone when it is administered in combination with pembrolizumab through Cmax.
Cmax will be assessed through the maximum measured plasma concentration occurring at Tmax tabulated by dose group.
To assess the pharmacokinetic profile of CFI-402411 alone when it is administered in combination with pembrolizumab through Tmax.
Tmax will be assessed by the time to achieve maximum plasma concentration and will be tabulated by dose group.
To assess the pharmacokinetic profile of CFI-402411 alone when it is administered in combination with pembrolizumab though Cmin.
Cmin will be calculated through the measured pre-dose plasma concentration and tabulated by dose group.
To assess the pharmacokinetic profile of CFI-402411 alone when it is administered in combination with pembrolizumab through T1/2.
Elimination half life will be calculated and tabulated by dose group.
To evaluate the effect of CFI-402411 treatment on immune- or disease related biomarkers.
The effects of CFI-402411 on pharmacodynamic biomarkers (cytokine levels) will be assessed by percent changes from baseline.

Full Information

First Posted
July 31, 2020
Last Updated
July 24, 2023
Sponsor
Treadwell Therapeutics, Inc
Collaborators
TIO Discovery Engine
search

1. Study Identification

Unique Protocol Identification Number
NCT04521413
Brief Title
Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies
Official Title
A First-In-Human, Phase 1/2 Study Of CFI-402411, a Hematopoietic Progenitor Kinase-1 (HPK1) Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Malignancies
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
August 31, 2020 (Actual)
Primary Completion Date
December 2023 (Anticipated)
Study Completion Date
June 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Treadwell Therapeutics, Inc
Collaborators
TIO Discovery Engine

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to test the safety of an investigational drug called CFI-402411 alone and in combination with pembrolizumab and to study its effects in patients with advanced solid tumors who have progressed following previous therapies.
Detailed Description
This study will be a first-in-human study evaluating the safety and tolerability of CFI-402411 in subjects with advanced solid malignancies, when CFI-402411 is administered as a single agent or in combination with pembrolizumab. CFI-402411 is an oral pill that blocks the function of HPK1. Blocking HPK1 could stimulate an immune response against the tumor in patients. This immune response could be further enhanced when combined with pembrolizumab. The data obtained from this study will determine the dose and schedule and subject selection for further clinical studies. Pre-clinical findings support further development of CFI-402411 as a novel anti-cancer agent, and the combination of CFI-402411 with pembrolizumab as a potential strategy to improve outcomes of subjects with advanced malignancies.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Advanced Solid Malignancies
Keywords
advanced tumors, pembro, keytruda, pembrolizumab, 2411, CFI-402411, first in human, first-in-human, hematopoietic progenitor kinase-1 inhibitor, HPK1, advanced solid malignancies, solid malignancies, TWT-101, TWT101, UHN, University Health Network, Treadwell Therapeutics

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Sequential Assignment
Model Description
Dose escalation and expansion for monotherapy and combination arms with pembrolizumab
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
170 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
A1: Monotherapy Escalation
Arm Type
Experimental
Arm Description
Dose escalation arm with CFI-402411. CFI-402411 is administered orally once daily.
Arm Title
A2: Monotherapy Biomarker
Arm Type
Experimental
Arm Description
Dose escalation biomarker arm with CFI-402411. CFI-402411 is administered orally once daily.
Arm Title
A3: Monotherapy Expansion
Arm Type
Experimental
Arm Description
Dose expansion arm with CFI-402411 at its recommended phase 2 dose.
Arm Title
B1: Combination Escalation
Arm Type
Experimental
Arm Description
Dose escalation arm with CFI-402411 in combination with pembrolizumab (at its labeled dose and schedule).
Arm Title
B2: Combination Expansion
Arm Type
Experimental
Arm Description
Dose expansion arm with the recommended phase 2 dose of CFI-402411 in combination with pembrolizumab (at its labeled dose and schedule).
Intervention Type
Drug
Intervention Name(s)
CFI-402411
Other Intervention Name(s)
2411, 402411
Intervention Description
CFI-402411 is administered orally once daily. The starting dose is 80 mg/day for escalation arms and the recommended dose for the expansion arms.
Intervention Type
Drug
Intervention Name(s)
Pembrolizumab
Other Intervention Name(s)
Keytruda, pembro
Intervention Description
Pembrolizumab will be given at its labeled dose and schedule, 200 mg administered as an intravenous infusion over 30 minutes every 3 weeks.
Primary Outcome Measure Information:
Title
To assess the incidence of adverse events of CFI-402411 as a single agent and at the recommended phase 2 dose (RP2D).
Description
The number of subjects who experience an adverse event that was possibly related to study drug.
Time Frame
48 months
Title
To assess the incidence of adverse events with CFI-402411 in combination with pembrolizumab and at the RP2D.
Description
The number of subjects who experience an adverse event that was possibly related to study drug.
Time Frame
48 months
Title
To examine best overall response rate in subjects treated at multiple dose levels of CFI-402411.
Description
Best overall response rate will be summarized by dose cohort and overall using the percent of patients in each tumor response category.
Time Frame
48 months
Title
To examine progression free survival in subjects treated at multiple dose levels of CFI-402411.
Description
Time from first dose to disease progression or death whichever occurs first will be calculated and summarized for all patients by dose cohort and overall.
Time Frame
48 months
Secondary Outcome Measure Information:
Title
To identify the maximum tolerated dose of single agent CFI-402411 alone and in combination with pembrolizumab.
Description
Safety tables and pharmacokinetic tables will be assessed.
Time Frame
48 months
Title
To further assess the incidence of adverse events of CFI-402411.
Description
The number of subjects who experience an adverse event that was possibly related to study drug.
Time Frame
48 months
Title
To assess best overall response of CFI-402411 monotherapy and in combination with pembrolizumab.
Description
Best overall response rate will be summarized by dose cohort and overall using the percent of patients in each tumor response category.
Time Frame
48 months
Title
To assess overall response rates of CFI-402411 monotherapy and in combination with pembrolizumab.
Description
For all subjects the overall response rates of complete response and partial response will be calculated and summarized by dose cohort and overall.
Time Frame
48 months
Title
To assess overall survival of CFI-402411 monotherapy and in combination with pembrolizumab.
Description
The time from first dose until the date of death from any cause will be calculated and summarized for all patients by dose cohort and overall.
Time Frame
48 months
Title
To assess progression free survival of CFI-402411 monotherapy and in combination with pembrolizumab.
Description
Time from first dose to disease progression or death whichever occurs first will be calculated and summarized for all patients by dose cohort and overall.
Time Frame
48 months
Title
To assess duration of response of CFI-402411 monotherapy and in combination with pembrolizumab.
Description
The time from the first objective response to the time of documented disease progression or death due to any cause, whichever occurs first, will be calculated and summarized for all patients by dose cohort and overall.
Time Frame
48 months
Title
To assess the pharmacokinetic profile of CFI-402411 alone when it is administered in combination with pembrolizumab through AUC.
Description
Area under the plasma concentration (AUC) versus time curve from time 0 to time of least measurable concentration tabulated by dose group.
Time Frame
48 months
Title
To assess the pharmacokinetic profile of CFI-402411 alone when it is administered in combination with pembrolizumab through Cmax.
Description
Cmax will be assessed through the maximum measured plasma concentration occurring at Tmax tabulated by dose group.
Time Frame
48 months
Title
To assess the pharmacokinetic profile of CFI-402411 alone when it is administered in combination with pembrolizumab through Tmax.
Description
Tmax will be assessed by the time to achieve maximum plasma concentration and will be tabulated by dose group.
Time Frame
48 months
Title
To assess the pharmacokinetic profile of CFI-402411 alone when it is administered in combination with pembrolizumab though Cmin.
Description
Cmin will be calculated through the measured pre-dose plasma concentration and tabulated by dose group.
Time Frame
48 months
Title
To assess the pharmacokinetic profile of CFI-402411 alone when it is administered in combination with pembrolizumab through T1/2.
Description
Elimination half life will be calculated and tabulated by dose group.
Time Frame
48 months
Title
To evaluate the effect of CFI-402411 treatment on immune- or disease related biomarkers.
Description
The effects of CFI-402411 on pharmacodynamic biomarkers (cytokine levels) will be assessed by percent changes from baseline.
Time Frame
48 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Key Inclusion Criteria: Study-Wide Eligibility (Across All Study Parts): Age > 18 years old Have progressed after ≥ 1, but no more than 3 regimens of systemic therapies for recurrent / metastatic disease. Subjects must have measurable disease. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Part A1: Monotherapy Dose Escalation Inclusion Criteria 1. Histological or cytological confirmation of advanced solid malignancy that is refractory to or not a candidate for current standard treatment(s) and for whom no standard therapy is available. Part A2: Biomarker-Focused Monotherapy Backfills Inclusion Criteria Histological or cytological confirmation of one of the advanced cancers listed below; NSCLC SCLC cutaneous melanoma Merkel cell carcinoma squamous cell carcinoma of head and neck, anal canal, or skin urothelial cancer clear cell or non-clear cell renal cell carcinoma triple negative breast cancer endometrial cancer (regardless of MSI status) cervical cancer gastroesophageal cancer hepatocellular cancer any histology if known to be microsatellite-instability high (MSI-H) Tumors must be refractory to or not a candidate for current standard treatment(s) and for whom no standard therapy exists. Part A3: Monotherapy Expansion Inclusion Criteria Histological or cytological confirmation of one of the advanced cancers listed below; NSCLC cancer any histology SCLC cutaneous melanoma Merkel cell carcinoma squamous cell carcinoma of head and neck, anal canal, or skin urothelial cancer clear cell or non-clear cell renal cell carcinoma triple negative breast cancer endometrial cancer (regardless of MSI status) cervical cancer gastroesophageal cancer hepatocellular any histology if known to be microsatellite-instability high (MSI-H) Tumors must be refractory to or subjects intolerant of current standard treatment(s) and for whom no standard therapies are available. Optional biopsies: Subjects that consent to optional fresh tumor biopsies must have at least one non-target soft tissue tumor lesion that can be biopsied. Part B1: CFI-402411 in Combination with Pembrolizumab Dose Escalation Inclusion Criteria Subjects must be deemed eligible by the Investigator to receive pembrolizumab. Histological or cytological confirmation of one of the advanced cancers listed below (list may vary in each country, USA shown here); NSCLC cancer any histology SCLC cutaneous melanoma Merkel cell carcinoma squamous cell carcinoma of head and neck, anal canal, or skin urothelial cancer clear cell or non-clear cell renal cell carcinoma triple negative breast cancer endometrial cancer (regardless of MSI status) cervical cancer gastroesophageal cancer hepatocellular cancer any histology if known to be microsatellite-instability high (MSI-H) Tumors must be refractory to or subjects intolerant of current standard treatment(s) or for whom no standard therapy is available. Part B2: CFI-402411 in Combination with Pembrolizumab Expansion Inclusion Criteria Subjects must be deemed eligible by the Investigator to receive pembrolizumab Histological or cytological confirmation of one of the advanced cancers listed below (list may vary in each country, USA shown here); non-small cell lung cancer any histology SCLC cutaneous melanoma Merkel Cell carcinoma squamous cell carcinoma of head and neck, anal canal, or skin urothelial cancer clear cell or non-clear cell renal cell carcinoma triple negative breast cancer endometrial cancer (regardless of MSI status) gastroesophageal cancer hepatocellular cancer any histology if known to be microsatellite-instability high (MSI-H) Tumors must be refractory to or subjects intolerant of current standard non-IO treatment(s) or for whom no standard therapy is available. Key Exclusion Criteria: Study-Wide Eligibility (Across All Study Parts) Subjects will be excluded from the study if any of the following criteria is met; Previous treatment with an HPK1 inhibitor in other clinical trials. Diagnosis of autoimmune-based disease or clinically significant auto-immune disorders. Have symptomatic congestive heart failure, active angina pectoris or recent myocardial infarction (within 6 mos). Have chronic atrial fibrillation. Known central nervous system metastasis. Stroke or transient ischemic attack, or other ischemic events or thromboembolic events within 3 months of study enrollment. A history of QTc prolongation or a marked baseline prolongation of QT/QTc interval or a history of additional risk factors for TdP (e.g., heart failure, hypokalemia, family history of Long QT Syndrome).
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Treadwell Therapeutics Clinical Trials
Phone
+1-416-455-7510
Email
clinicaltrials@treadwelltx.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Omid Hamid, Dr
Organizational Affiliation
The Angeles Clinic, Los Angeles
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of California San Diego
City
La Jolla
State/Province
California
ZIP/Postal Code
92093
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ceonne Kim
Email
cek008@health.ucsd.edu
Facility Name
The Angeles Clinic
City
Los Angeles
State/Province
California
ZIP/Postal Code
90025
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michele Azada
Email
mazada@theangelesclinic.org
Facility Name
Yale Cancer Center
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06519
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ingrid Palmer
Email
ingrid.palma@yale.edu
Facility Name
Florida Cancer Specialists
City
Sarasota
State/Province
Florida
ZIP/Postal Code
34232
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Donna Jones
Email
djones@flcancer.com
Facility Name
START - Mid-West
City
Grand Rapids
State/Province
Michigan
ZIP/Postal Code
49546
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Robinson Katie
Email
katie.robinson@startmidwest.com
Facility Name
SCRI - Nashville
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37023
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Miller Elizabeth
Email
asksarah@sarahcannon.com
Facility Name
MD Anderson
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Munir Chowdhury
Email
MChowdhury@mdanderson.org
Facility Name
START - San Antonio
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Isabel Jimenez
Email
isabel.jimenez@startsa.com
Facility Name
Virginia Cancer Specialist
City
Fairfax
State/Province
Virginia
ZIP/Postal Code
22031
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Melissa Hackmaster
Email
melissa.hackmaster@usoncology.com
Facility Name
Cross Cancer Institute
City
Edmonton
State/Province
Alberta
ZIP/Postal Code
T6G1Z2
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Carly Mack
Email
Carly.Mack@albertahealthservices.ca
Facility Name
The Ottawa Hospital
City
Ottawa
State/Province
Ontario
ZIP/Postal Code
K1H8L6
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Scott Laurie
Facility Name
Princess Margaret Cancer Centre
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5G2M9
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ashley Adile
Email
ashley.adile@uhn.ca
Facility Name
Prince of Wales Hospital
City
Sha Tin
Country
Hong Kong
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jane Koh
Email
Jane@clo.cuhk.edu.hk

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
It is too early to determine whether we will make IPD available - we do not yet have a process written on this. Field will be updated once our policy / process is written.

Learn more about this trial

Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies

We'll reach out to this number within 24 hrs